From Nasdaq: 2025-02-24 10:29:00

The fourth-quarter 2024 earnings season for the Medical sector is wrapping up, with strong results reported by major companies like Johnson & Johnson. Overall, the sector is expected to see a 13.8% increase in earnings and a 9.3% rise in sales from the year-ago quarter. Viatris, Perrigo, Novavax, Intellia Therapeutics, and Iovance Biotherapeutics are set to report earnings on Feb. 27, 2025.

As of Feb. 19, 85.2% of Medical sector companies have reported earnings, with 82.7% beating earnings estimates. Earnings have increased by 14.2% year over year, while revenues have risen by 9.4%. The sector is expected to see a 13.8% increase in earnings and a 9.3% rise in sales from the year-ago quarter.

Viatris, a generic drugmaker, has a mixed earnings surprise history. For the upcoming quarter, the company has an Earnings ESP of -3.51% and a Zacks Rank #4 (Sell). Strong performance in Emerging Markets and other regions is expected to boost sales.

Perrigo, known for its consumer self-care products, has a mixed earnings history. For the upcoming quarter, the company has an Earnings ESP of -4.92% and a Zacks Rank #4. Revenues from its segments are expected to decline due to lower sales in the United States.

Novavax has had a mixed earnings history, with a negative four-quarter surprise average of 56.95%. For the upcoming quarter, the company has an Earnings ESP of -48.54% and a Zacks Rank #3. Minimal vaccine sales are expected during this period.

Intellia Therapeutics has a mixed earnings history and is expected to beat estimates in the upcoming quarter. The company has an Earnings ESP of +35.03% and a Zacks Rank #2. Collaboration revenues and updates on clinical-stage pipeline candidates are anticipated.

Iovance Biotherapeutics has a mixed earnings history and is expected to beat estimates in the upcoming quarter. The company has an Earnings ESP of +7.90% and a Zacks Rank #4. Revenues are likely to be boosted by sales of its marketed drugs, including Proleukin and Amtagvi.



Read more at Nasdaq: What’s in Store for These 5 Biotech Stocks This Earnings Season?